Oncolytic viruses (OVs) combined with radiotherapy (RT) have shown promise in clinical trials but remain limited by unsatisfactory efficacy. Key challenges include poor intravenous delivery, insufficient RT-induced DNA damage, and suboptimal anti-tumor immune responses. Herein, we developed a novel ...
ORGANISM(S): Homo Sapiens Mus Musculus
